Skip to main content
OpenTrials
Completed

NCT Number: NCT01919762

Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)

To assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Bacteremia Assay.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This protocol is intended for use by external sites collecting clinical research specimens for T2 Biosystems' use in developing the T2Bacterial Assay. Specimens and information on patients' medical history, blood properties, medications, and blood culture history/results are required from the T2Bacterial Assay's target patient population (i.e., candidates for blood culture). Ideally, clinical specimens for use in developing the T2Bacterial Assay will be collected from negative blood culture, positive non-bacteria blood culture and positive bacteria blood culture patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject or subject's authorized representative must be able to understand, read and sign the study specific informed consent form after the nature of the study has been fully explained to them.
  • Males and females 18 - 95 years of age.

For Group A,

  • Subject is confirmed to have bacteremia (gram negative rods, gram negative coccobacillus, and/or gram positive cocci) as evidenced by a positive diagnostic blood culture
  • Subsequent species identification identifies the presence of one of the following 6 species of bacteria:
  • Acinetobacter baumannii
  • Staphylococcus aureus
  • Klebsiella pneumonia
  • Pseudomonas aeruginosa
  • Enterococcus faecalis
  • Enterococcus faecium

For Group B,

  • Males and females 18 - 95 years of age.
  • Subject is confirmed to not have bacteremia from the 6 bacteria species targeted by this study, as evidenced by diagnostic blood culture and subsequent species identification.

Exclusion criteria

  • Use of any novel (i.e. not commercially available) drug compound within 30 days prior to the collection of T2 blood specimens.
  • Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study.
  • Subject has had an anti-bacterial drug administered through the same port or central line as is used to collect the clinical research specimens. A line draw cannot be used to obtain a study sample if an antibacterial agent was administered intravenously within the last 72 hours, unless the site can specifically document that a different line was used to administer the anti-bacterial agent.

Treatment and study plan

Primary outcomes

  1. Number of bacteremia positive patients

    Time frame: 3-5 days post blood culture

    Number of bacteria positive patients based on concordant, sequential blood culture results and a positive T2 signal

Secondary outcomes

  1. Number of bacteremia negative patients

    Time frame: 3-5 Days post blood culture

    Number of negative bacteremia samples based on concordant, sequential blood culture results and a negative T2 signal

Sponsors and collaborators

Lead sponsor

T2 Biosystems

Industry

Registry information

Official study title

Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)-Part I (Prospective Collection and Freezing of Whole Blood Specimens)

Acronym: DIREBT

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Aug 9, 2013
Registry last updated
Sep 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.